Non-transplant salvage therapy for low-risk relapsed/refractory pediatric classical Hodgkin lymphoma (cHL) had high rates of ...

Guillermo 'Memo' del Bosque passed away after battling a rare cancer for over 5 years. He died on Monday, April 7, at the age ...

Discover how innovative lymphoma treatments are transforming patient outcomes, from targeted therapies to immunotherapy ...

Memo del Bosque was diagnosed with Hodgkin’s lymphoma in 2017. This aggressive cancer primarily affects white blood cells ...

Patients with relapsed and refractory HL have an increased chance of cure with HDT and ASCT, which can be estimated at approximately 50-60%. All outcomes are better in late relapses and if ...

Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science ...

And for many people with these cancers, like Laura, relapse scenarios are all too familiar. But treatment options for NHL are on the rise. Rising rates of non-Hodgkin's lymphoma in the U.S. are ...

Explore the impact of functional respiratory tests on outcomes in anti-CD19 CAR T-cell therapy, presented at EBMT 2025.

In 1997, rituximab received approval for use by the United States Food and Drug Administration (US FDA) for the treatment of patients with relapsed low-grade non-Hodgkin lymphomas. It was the ...